BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by State Street Corp

State Street Corp reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,849,588 shares of the biotechnology company’s stock after selling 497,211 shares during the period. State Street Corp owned about 4.27% of BioCryst Pharmaceuticals worth $67,257,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC boosted its holdings in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the period. nVerses Capital LLC acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $63,000. Finally, Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $82,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $7.49 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -12.28 and a beta of 1.79. The stock has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $7.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.19) EPS. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on BCRX. Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.